Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: Clinicopathologic and prognostic significance of matrilysin expression

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1118-1127

  Yamamoto, H ^a   Itoh, F ^a   Iku, S ^a   Adachi, Y ^a   Fukushima, H ^a   Sasaki, S ^a   Mukaiya, M ^a   Hirata, K ^a   Imai, K ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; CANCER GROWTH; CANCER INVASION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STROMA CELL; SURVIVAL RATE;

EID: 0035865438     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1118     Document Type: Article

References (64)

1. Cancer statistics, 1999
2. Pancreatic cancer
3. Ductal adenocarcinoma of the pancreas head: Survival after regional versus extended lymph-adenectomy
4. Pancreatic cancer: The potential clinical relevance of alterations in growth factors and their receptors
5. Molecular genetics of exocrine pancreatic neoplasms
6. Frequent somatic mutations and homozygous deletions of the p16 (MTSI) gene in pancreatic adenocarcinoma
7. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
8. Matrilysin: An epithelial matrix metalloproteinase with potentially novel functions
9. Matrilysin
10. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice
11. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenecity in vivo
12. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma
13. Relation of matrilysin messager RNA expression with invasive activity in human gastric cancer
14. Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma
15. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin
16. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis
17. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers
18. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers
19. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma
20. Suppression of matrilysin inhibits colon cancer cell invasion in vitro
21. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model
22. Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro
23. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: Selection of a biologically active and tolerable dose for longer-term studies
24. Marimastat in recurrent colorectal cancer: Exploratory evaluation of biological activity by measurement of carcinoembryonic antigen
25. Marimastat in patients with advanced pancreatic cancer: A dose-finding study
26. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer
27. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma
28. Expression of matrilysin in vascular endothelial cell adjacent to matrilysin-producing tumor
29. Matrix metalloproteinases: Multifunctional contributors to tumor progression
30. Stromal degradation by the malignant epithelium in pancreatic cancer and the therapeutic potential of proteolytic inhibition
31. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer
32. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma
33. Expression of membrane-type matrix metalloproteinase-1 in human pancreatic adenocarcinomas
34. Expression of the MMP-1 in human pancreatic carcinoma: Relationship with prognostic factor
35. Role of MT-MMPs and MMP-2 in pancreatic cancer progression
36. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer
37. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of PANC-1 cells in vitro
38. Effect of matrix metalloproteinase inhibition on pancreatic cancer invasion and metastasis: An additive strategy for cancer control
39. Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolong survival in a murine model of human pancreatic cancer
40. TNM classification of malignant tumors
41. Enhanced secretion and activation of matrilysin during malignant conversion of human colorectal epithelium and its relationship with invasive potential of colon cancer cells
42. Enhanced production and activation of matrix metalloproteinase-7 (matrilysin) in human endometrial carcinomas
43. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas
44. Matrix metalloproteinases and their inhibitors in gastric cancer
45. Matrix metalloproteinase-9 (92 kDa gelatinase/type IV collagenase) from U937 monoblastoid cells: Correlation with cellular invasion
46. Activation mechanisms of matrix metalloproteinases
47. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells: Activation of the precursor, interaction with other matrix metalloproteinases and enzymatic properties
48. Characterization of trypsinogens 1 and 2 in two human pancreatic adenocarcinoma cell lines: CFPAC-1 and CAPAN-1
49. Matrilysin as a target for chemotherapy for colon cancer: Use of antisense oligonucleotides as antimetastatic agents
50. Pancreatic trypsinogen and cathepsin B in human pancreatic carcinomas and associated metastatic lesions
51. The matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium
52. Processing of tumour necrosis factor-alpha precursor by metalloproteinases
53. Diphtheria toxin endocytosis and membrane translocation are dependent on the intact membrane-anchored receptor (HB-EGF precursor): Studies on the cell-associated receptor cleaved by a metalloprotease in phorbol-estertreated cells
54. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis
55. Influence of organ environment on extracellular matrix degradative activity and metastasis of human colon carcinoma cells
56. Expression of matrilysin mRNA in colorectal adenomas and its induction by truncated fibronectin
57. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer
58. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis
59. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1
60. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases
61. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence
62. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer
63. Tissue inhibitors of matrix metalloproteinases in tumor growth
64. Changing views of the role of matrix metalloproteinases in metastasis